+31 (0)317 466 260 info@amrif.eu

Diabetes

Background

AMRIF has obtained a panel of patents in using Alkaline Phosphatase to treat Diabetes.

There are more than 250 million type 2 diabetes patients worldwide, of which 30% suffer from diabetic complications, including foot ulcers, retinopathy, kidney disease and pre-eclampsia.

How does RESCAP® treat diabetes and its complications?

RESCAP® functions are well positioned to prevent and treat Diabetes and its complications:

  • Reduces systemic inflammation
  • Improves insulin sensitivity
  • Normalizes blood glucose levels
  • Protects the gut barrier
  • Protects key organs against lipotoxicity (fat accumulation)

 

RESCAP® will be supplimented orally to type 2 diabetes patients once daily, to prevent and treat diabetic complicaiton.

 

Literature

Moss et al. Intestinal alkaline phosphatase inhibits the proinflammatory nucleotide uridine diphosphate. Am J Physiol Gastrointest Liver Physiol 2013; 304(6): G597-G604.

Malo et al. Intestinal alkaline phosphatase preserves the normal homeostasis of gut microbiota. Gut 2010; 59(11): 1476-84

Kaliannan et al. Intestinal alkaline phosphatse prevents metabolic syndrome in mice. PNAS 2013; vol. 110 no. 17 7003-7008